Genticel Reports Additional Results at 12 Months From Phase

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001

PARIS and TOULOUSE, France, April 20, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today reports additional results at 12 months from the phase 2 clinical study of the Company’s immunotherapeutic candidate, GTL001, designed to clear HPV 16 and/or 18 infection.  

Initial results at 12 months of the GTL001 phase 2 study, announced on January 27, 2016,  showed clear statistical separation (p=0.018) in the predefined subgroup of patients with normal cytology (NILM 1 ), which comprises about 75% in GTL001’s target population 2 . In addition, post-hoc analyses demonstrated a trend towards statistical significance in the subgroup of patients with undetermined cellular anomalies (ASCUS 1 ).

Based on these results, the combined group of patients with normal cytology (NILM 1 ) and patients with undetermined cellular anomalies (ASCUS 1 ) also demonstrates a statistically significant separation (p= 0.0029). This combined group of patients who do not yet have low-grade lesions (LSIL 1 ) comprises the vast majority (over 80%) of the HPV-positive women GTL001 aims to treat.

" These very encouraging complementary data are indicative of the potential of GTL001 to provide a therapeutic solution to a large majority of the women infected with the two most dangerous types of HPV. While these results are subject to confirmation by data at 18 and then 24 months, they are extremely encouraging and validate the biologic activity of GTL001 in HPV 16/18-positive subjects prior to the onset of low-grade lesions,” said Benedikt Timmerman, PhD., MBA, CEO of Genticel.

He added, “ These phase 2 study results provide us with the opportunity to appropriately refine our clinical development plan for GTL001, going forward. We now confidently await the conclusion of this study, which is expected during the first quarter of 2017. ”

Summary of Subgroup Analyses

Viral clearance at 12 months GTL001 Placebo p-value
Normal cytology  (NILM)                          – predefined group   20/32 (62.5%) 12/30 (40%) 0.018*
Undetermined cellular anomalies (ASCUS)       – post-hoc 17/31 (54.8%) 12/34 (35.3%) 0.067*
Total NILM and ASCUS                                           – post-hoc 37/63 (58.7%) 24/64 (37.5%) 0.0029*
Low-grade lesions (LSIL)                                       – post-hoc 20/54 (37.0%) 22/51 (43.1%) 0.560*
Overall population               – predefined primary endpoint 57/117 (48.7%) 46/116 (39.7%) 0.188**

* : Cochran-Mantel-Haenszel test controlling stratification factors : HPV type, cytology and age. **: Fisher exact test.

_______________________________

1   NILM: Negative for Intraepithelial Lesion or Malignancy; ASCUS: Atypical Squamous Cells of Undetermined Significance; LSIL: low-grade squamous intraepithelial lesion.

2  Wright et al. Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015: 136; 189-197 .

About GTL001 Phase 2 (RHEIA-VAC) Clinical Trial

The phase 2 trial is an ongoing randomized double-blind, placebo controlled study which enrolled 239 HPV 16/18-positive patients at 39 investigational sites in 7 Western Europe countries. The trial consists of a treated arm with 117 patients and a placebo arm with 116 patients. A total of 233 evaluable patients are included in the topline results per protocol efficacy analysis.

Enrolled patients are required to be HPV 16 and/or 18 positive with normal, LSIL or ASCUS cytology. Patients with CIN2+ were excluded by colposcopy/histology. All patients received either 2 inter-dermal injections of 600 µg of GTL001 or 2 inter-dermal injections of placebo 6 weeks apart, and in both cases 2 applications of imiquimod cream 5%, 15 minutes and 24 hours after each injection of vaccine or placebo. The patients in both arms who received the full dose of vaccine or placebo were assessed for viral clearance at 12 months as the primary endpoint, and for secondary endpoints including maintenance of viral clearance and progression to CIN2+.

Viral clearance is assessed using a type specific, sensitive and quantitative HPV PCR assay. All patients in the trial continue to be followed for safety at 18 and 24 months and efficacy at 15, 18 and 24 months after their second injection. Additional data, including maintenance of viral clearance, viral load dynamics, and progression to CIN2+ will be evaluated. Additional study details are available at https://clinicaltrials.gov/ct2/show/NCT01957878 .

About Genticel

Aiming to solve a public health issue.

Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001, its first-in-class immunotherapeutic candidate. GTL001 is more than halfway through a 24-month proof of concept Phase 2 trial in Europe.

Offering a promising technological platform.

Genticel’s versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel’s second candidate, GTL002, is a multivalent HPV immunotherapeutic candidate designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.

Focusing on value creation.

Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addition to this attractive HPV product pipeline, Genticel’s versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIL), the world’s largest producer of vaccine doses. This partnership could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable SIIL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.

More information at www.genticel.com

Disclaimer

This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genticel shares in any country. This press release may contain forward-looking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company’s management and are subject to risks and uncertainties such as the company’s ability to implement its chosen strategy, customer market trends, changes in technologies and in the company’s competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company’s growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document   filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015 and those linked to changes in economic conditions, the financial markets, or the markets on which Genticel is present. Genticel products are currently used for clinical trials only and are not otherwise available for distribution or sale.

CONTACT: GENTICEL Valerie Leroy Investor Relations & Corporate Communications +33 6 33 34 37 30 investors@genticel.com INVESTORS US - LifeSci Advisors Brian Ritchie +1 212 915 2578 britchie@lifesciadvisors.com Europe - ACTUS Corinne Puissant +33 1 53 67 36 77 cpuissant@actus.fr MEDIA ALIZE RP Caroline Carmagnol & Florence Portejoie +33 6 64 18 99 59 / +33 6 47 38 90 04 genticel@alizerp.fr

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 6

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 138

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 41

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 179

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 61

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 153

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 114

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 192

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 56

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Market Dynamics: Dollar Strength and Economic Trends

Updated Category News Views 280

Understanding Current Market Trends In today's financial landscape, the dollar has been showing significant strength, propelled largely by the increasing yields of U.S. Treasuries. This upswing marks the dollar reaching levels not seen in nearly three months against both the euro and the yen, signaling contrasting economic conditions across these regions. Economic...

Continue Reading
Bitcoin Surpasses $99K: Insights on Market Movements

Updated Category News Views 245

Bitcoin's Impressive Recovery Journey Bitcoin has displayed remarkable resilience in the market, experiencing gains for the seventh consecutive day with its price hitting $99,513.7. This uptrend comes after a challenging year-end period that saw a significant dip in value. As investors closely monitor the evolving regulatory outlook in the United States under the...

Continue Reading
StoneX Group Inc. Prepares for First Quarter Earnings Release

Updated Category News Views 102

StoneX Group Inc. Prepares for Earnings Release StoneX Group Inc. (NASDAQ: SNEX) is gearing up to share its fiscal 2025 first quarter financial results. This release is scheduled for a date soon to come, creating excitement within the investment community. As a part of its commitment to transparency and investor engagement, the company will host a conference call the...

Continue Reading
Down4Sound Introduces High-Power DVX Subwoofer Series

Updated Category News Views 82

Down4Sound Launches Exciting New DVX Subwoofer Series Down4Sound, a renowned name in high-performance car audio systems, has announced the introduction of their groundbreaking DVX Subwoofer Series. This innovative product line promises to redefine audio experiences for enthusiasts everywhere, boasting a phenomenal 1700W RMS power output across multiple size options to...

Continue Reading
Jozu Boosts AI Deployment Speed and Strengthens Security Efforts

Updated Category News Views 365

Accelerating AI Deployment with Jozu Jozu has unveiled an innovative enterprise AI orchestration platform that significantly reduces the time required for deploying AI applications while enhancing security and compliance protocols. This platform addresses the increasing demands faced by organizations in managing AI applications effectively. Enhancing AI Management Across...

Continue Reading